Risk factors
Zevra Therapeutics (ZVRA) risk factors
Item 1A of every Zevra Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors42 risks16 new89 dropped25 reworded
Zevra relies heavily on MIPLYFFA for 82% of revenue and faces intense pricing, manufacturing, and distribution risks.
Filed Mar 09, 2026 - FY2024 10-K risk factors115 risks
Zevra relies heavily on the commercial success of its rare disease products MIPLYFFA and OLPRUVA. Market adoption depends on physician acceptance, third-party payor reimbursement, and competing therapies like AQNEURSA. Strict regulatory compliance, including FDA post-approval requirements and controlled substance laws, governs product manufacturing and distribution.
Filed Mar 12, 2025